BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23062537)

  • 1. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort.
    Olde Nordkamp LR; Dabiri Abkenari L; Boersma LV; Maass AH; de Groot JR; van Oostrom AJ; Theuns DA; Jordaens LJ; Wilde AA; Knops RE
    J Am Coll Cardiol; 2012 Nov; 60(19):1933-9. PubMed ID: 23062537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution.
    Jarman JW; Lascelles K; Wong T; Markides V; Clague JR; Till J
    Eur Heart J; 2012 Jun; 33(11):1351-9. PubMed ID: 22408031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience.
    Aydin A; Hartel F; Schlüter M; Butter C; Köbe J; Seifert M; Gosau N; Hoffmann B; Hoffmann M; Vettorazzi E; Wilke I; Wegscheider K; Reichenspurner H; Eckardt L; Steven D; Willems S
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):913-9. PubMed ID: 22923274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands.
    Heersche JH; Blom NA; van de Heuvel F; Blank C; Reimer AG; Clur SA; Witsenburg M; ten Harkel AD
    Pacing Clin Electrophysiol; 2010 Feb; 33(2):179-85. PubMed ID: 20025697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure.
    Spencker S; Coban N; Koch L; Schirdewan A; Müller D
    Europace; 2009 Apr; 11(4):483-8. PubMed ID: 19103654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome after implantation of a cardioverter-defibrillator in patients with Brugada syndrome: a multicenter study-part 2.
    Sacher F; Probst V; Maury P; Babuty D; Mansourati J; Komatsu Y; Marquie C; Rosa A; Diallo A; Cassagneau R; Loizeau C; Martins R; Field ME; Derval N; Miyazaki S; Denis A; Nogami A; Ritter P; Gourraud JB; Ploux S; Rollin A; Zemmoura A; Lamaison D; Bordachar P; Pierre B; Jaïs P; Pasquié JL; Hocini M; Legal F; Defaye P; Boveda S; Iesaka Y; Mabo P; Haïssaguerre M
    Circulation; 2013 Oct; 128(16):1739-47. PubMed ID: 23995538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults.
    Bettin M; Larbig R; Rath B; Fischer A; Frommeyer G; Reinke F; Köbe J; Eckardt L
    JACC Clin Electrophysiol; 2017 Dec; 3(13):1499-1506. PubMed ID: 29759830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients.
    Berul CI; Van Hare GF; Kertesz NJ; Dubin AM; Cecchin F; Collins KK; Cannon BC; Alexander ME; Triedman JK; Walsh EP; Friedman RA
    J Am Coll Cardiol; 2008 Apr; 51(17):1685-91. PubMed ID: 18436121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term single-center experience of defibrillator therapy in children and adolescents.
    Frommeyer G; Feder S; Bettin M; Debus V; Köbe J; Reinke F; Uebing A; Eckardt L; Kehl HG
    Int J Cardiol; 2018 Nov; 271():105-108. PubMed ID: 29885825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.